8-K Announcements
6Material company update
May 15, 2026·SEC
Material company update
Mar 18, 2026·SEC
Material company update
Feb 2, 2026·SEC
ProKidney Corp.(PROK)Earnings, Financials & Key Ratios
PROK•NASDAQ
$1.95
Price updated Jul 7, 2026
AboutProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.Show more
- Revenue$893K+1075.0%
- EBITDA-$158M+11.1%
- Net Income-$69M-12.7%
- EPS (Diluted)-0.52+16.1%
- Gross Margin100%
- EBITDA Margin-17741.55%+92.4%
- Operating Margin-18477.83%+92.4%
- Net Margin-7725.2%+90.4%
- ROE-19.64%-27.3%
PROK Price & Volume
ProKidney Corp. (PROK) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Negligible Revenue Growth
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical Trial Funding Runway
Key Thesis Takeaways
- ProKidney remains a high-risk, pre-commercial biotechnology entity heavily reliant on the successful execution of its REACT platform Phase III clinical trials.
- The company's financial profile is characterized by extreme R&D intensity, with quarterly outlays exceeding $33 million, which continues to erode the capital base and drive a $1.0 billion negative equity position.
- Investors should monitor the sustainability of the current $101.9 million cash position, as the lack of meaningful commercial revenue suggests a continued reliance on external financing to bridge the gap toward potential regulatory milestones.
Verdict Logic
the company's reliance on cash-intensive clinical development without commercial revenue, evidenced by a -201.2% FCF margin, presents a substantial risk to long-term solvency.
PROK Growth Metrics
ProKidney Corp. (PROK) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM190.52%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-9.36%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM8.33%
Return on Capital
10 Years-160.97%
5 Years-92.89%
3 Years-41.99%
Last Year-46.5%
PROK Recent Earnings
ProKidney Corp. (PROK) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 3/12 qtrs (100%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.14-7.7%
$0.13
Rev
$226,000+125.4%
$100,250
Q2 2026
Mar 18, 2026Metric
Actual
Est
EPS
$0.14+12.5%
$0.16
Rev
$223,000+37066.7%
$600
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.12+0.0%
$0.12
Rev
$217,000
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.13+7.1%
$0.14
Rev
$221,000+399.4%
$44,250
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.14vs $0.13-7.7% | $226,000vs $100,250+125.4% |
| Q2 2026 | Mar 18, 2026 | $0.14vs $0.16+12.5% | $223,000vs $600+37066.7% |
| Q4 2025 | Nov 10, 2025 | $0.12vs $0.12+0.0% | $217,000 |
| Q3 2025 | Aug 12, 2025 | $0.13vs $0.14+7.1% | $221,000vs $44,250+399.4% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for ProKidney Corp. (PROK)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.95 | $276.88M | -3.75 | 1075% | -7725.2% | -19.64% | — | |
| $4.07 | $444.42M | -2.02 | — | — | -70.79% | — | |
| $3.02 | $352.01M | -2.63 | -51.24% | -2056.79% | -58.89% | — | |
| $17.43 | $1.96B | -4.57 | 16.92% | -597.04% | -57.27% | — | |
| $37.92 | $3.9B | -46.81 | 120.01% | -49.17% | -5.89% | — | |
| $139.83 | $7.89B | 162.59 | 16.36% | 6.73% | 2.46% | — |
Compare PROK vs Peers
ProKidney Corp. (PROK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PROK SEC Filings & Documents
ProKidney Corp. (PROK) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when PROK posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PROK Frequently Asked Questions
ProKidney Corp. (PROK) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is ProKidney Corp.'s revenue?
ProKidney Corp. (PROK) reported $0.9M in revenue for fiscal year 2025.
How fast is ProKidney Corp. growing?
ProKidney Corp. (PROK) grew revenue by 1075.0% over the past year. This is strong growth.
Is PROK profitable?
ProKidney Corp. (PROK) reported a net loss of $74.8M for fiscal year 2025.
Dividend & Returns
What is PROK's return on equity?
ProKidney Corp. (PROK) has a return on equity (ROE) of -19.6%. Negative ROE indicates the company is unprofitable.
What is ProKidney Corp.'s free cash flow?
ProKidney Corp. (PROK) had negative free cash flow of $150.1M in fiscal year 2025, likely due to heavy capital investments.